CoChat

Obesity-Associated GNAS Mutations and the Melanocortin Pathway

Open access
Mendes de Oliveira, Edson, Keogh, Julia M., Talbot, Fleur, Henning, Elana, Ahmed, Rachel, Perdikari, Aliki, Bounds, Rebecca, Wasiluk, Natalia, Ayinampudi, Vikram, Barroso, Inês, Mokrosiński, Jacek, Jyothish, Deepthi, Lim, Sharon, Gupta, Sanjay, Kershaw, Melanie, Matei, Cristina, Partha, Praveen, Randell, Tabitha, McAulay, Antoinette, Wilson, Louise C., Cheetham, Tim, Crowne, Elizabeth C., Clayton, Peter, Farooqi, I. Sadaf · 2021 · New England Journal of Medicine
Cited by 95

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

BACKGROUNDGNAS encodes the Gα s (stimulatory G-protein alpha subunit) protein, which mediates G protein-coupled receptor (GPCR) signaling.GNAS mutations cause developmental delay, short stature, and skeletal abnormalities in a syndrome called Albright's hereditary osteodystrophy.Because of imprinting, mutations on the maternal allele also cause obesity and hormone resistance (pseudohypoparathyroidism). METHODSWe performed exome sequencing and targeted resequencing in 2548 children who presented with severe obesity, and we unexpectedly identified 22 GNAS mutation carriers.We investigated whether the effect of GNAS mutations on melanocortin 4 receptor (MC4R) signaling explains the obesity and whether the variable clinical spectrum in patients might be explained by the results of molecular assays. RESULTS Almost all GNAS mutations impaired MC4R signaling.A total of 6 of 11 patients who were 12 to 18 years of age had reduced growth.In these patients, mutations disrupted growth hormone-releasing hormone receptor signaling, but growth was unaffected in carriers of mutations that did not affect this signaling pathway (mean standard-deviation score for height, -0.90 vs. 0.75, respectively; P = 0.02).Only 1 of 10 patients who reached final height before or during the study had short stature.GNAS mutations that impaired thyrotropin receptor signaling were associated with developmental delay and with higher thyrotropin levels (mean [±SD], 8.4±4.7 mIU per liter) than those in 340 severely obese children who did not have GNAS mutations (3.9±2.6 mIU per liter; P = 0.004). CONCLUSIONSBecause pathogenic mutations may manifest with obesity alone, screening of children with severe obesity for GNAS deficiency may allow early diagnosis, improving clinical outcomes, and melanocortin agonists may aid in weight loss.GNAS mutations that are identified by means of unbiased genetic testing differentially affect GPCR signaling pathways that contribute to clinical heterogeneity.Monogenic diseases are clinically more variable than their classic descriptions suggest.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2103329

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

Metadata

Authors
Mendes de Oliveira, E., Keogh, J. M., Talbot, F., Henning, E., Ahmed, R., Perdikari, A., Bounds, R., Wasiluk, N., Ayinampudi, V., Barroso, I., Mokrosiński, J., Jyothish, D., Lim, S., Gupta, S., Kershaw, M., Matei, C., Partha, P., Randell, T., McAulay, A., Wilson, L. C., Cheetham, T., Crowne, E. C., Clayton, P., & Farooqi, I. S.
Venue
New England Journal of Medicine
Published
2021-10-21
Volume
385
Issue
17
Pages
1581-1592
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W3204307086
Cited by
95
References
7
FWCI
7.43
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.